Immix Biopharma
(NASDAQ) IMMX
Immix Biopharma Financials at a Glance
Market Cap
$743.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$34.98M
EPS (TTM)
-$0.92
P/E Ratio
-11.36
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$12.02
Volume
4,234,160.968
Open
$10.59
Price
$12.02
Volume
4,234,160.968
Open
$10.59
Previous Close
$10.45
Daily Range
$10.05 - $12.14
52-Week Range
$1.94 - $12.14
Estimated Earnings Date
Aug 14, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$12.02
Volume
4,234,160.968
Open
$10.59
Previous Close
$10.45
Daily Range
$10.05 - $12.14
52-Week Range
$1.94 - $12.14
Estimated Earnings Date
Aug 14, 2026
IMMX News
IMMX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Immix Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
21
CEO
Ilya Rachman, MD, PhD
Website
www.immixbio.comHeadquarters
Los Angeles, CA 90064, US
IMMX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-73.23%
Return on Capital
-28.68%
Return on Assets
-36.51%
Earnings Yield
-8.80%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$743.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
71.19M
Volume
4.23M
Avg. Volume
1.40M
Financials (TTM)
Gross Profit
-$130.77K
Operating Income
-$36.08M
EBITDA
-$34.56M
Operating Cash Flow
-$32.07M
Capital Expenditure
-$697.70K
Free Cash Flow
-$32.77M
Cash & ST Invst.
$90.58M
Total Debt
$1.04M
Immix Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$130.77K
N/A
Gross Margin
0.00%
N/A
Market Cap
$743.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$41.33M
N/A
Employees
18
N/A
Net Income
-$10.09M
-122.1%
EBITDA
-$9.96M
-122.6%
Quarterly Fundamentals
Total Cash
$90.58M
+468.9%
Total Debt
$1.04M
-2.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$912.34K
-7.9%
Short Term Debt
$125.39K
+84.9%
Return on Assets
-36.51%
N/A
Return on Invested Capital
-42.31%
N/A
Free Cash Flow
-$9.86M
-462.5%
Operating Cash Flow
-$9.83M
-483.2%